#United States #New York #Class Action #The Gross Law Firm #Regeneron Pharmaceuticals

Investors of Regeneron Pharmaceuticals Urged to Participate in Class Action Lawsuit

The Gross Law Firm has issued an important notice regarding a class action lawsuit involving Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who acquired shares within the specified class period are strongly encouraged to reach out to the firm for potential lead plaintiff opportunities. It's important to note that participating as a lead plaintiff is not a requirement for receiving any recovery from the lawsuit.

Details of the Class Action

Class Period

The relevant class period spans from November 2, 2023, to October 30, 2024. Shareholders are advised to act promptly and register their information to become part of this class action.

Allegations Against Regeneron

The lawsuit claims that Regeneron's executives made materially false or misleading statements during the class period, which had significant implications for the company's stock. Some of the central allegations include the following:

• - Concealment of Credit Card Fees: It is asserted that Regeneron was paying credit card fees to distributors, contingent upon those distributors not charging customers more when using credit cards to purchase Eylea, one of Regeneron’s key drugs.
• - Price Subsidization: Allegations suggest that these undisclosed payments effectively subsidized the pricing for customers using credit cards, giving Regeneron a competitive advantage in the marketplace and misleadingly inflating Eylea’s reported sales figures.
• - False Reporting: The firm claims that Regeneron's failure to disclose these credit card payments as price concessions led to a distorted average selling price (ASP) reported to federal agencies, thereby constituting a potential violation of the False Claims Act.
• - Deceptive Corporate Communications: Due to the factors above, statements made by Regeneron regarding the company’s business, operations, and outlook were reportedly materially misleading.

Next Steps for Shareholders

The deadline for shareholders to take action as potential lead plaintiffs is set for March 10, 2025. Interested shareholders are urged to enroll and register for this class action, as participation does not incur any costs or obligations. After registering, they will receive status updates via a monitoring software about the lawsuit's progression.

The Gross Law Firm, which boasts a reputation as a leading national class action law firm, aims to safeguard the rights of investors affected by deceptive practices. Their mission is to hold companies accountable for engaging in unethical business conduct that results in financial losses for shareholders.

Contact Information

Those interested in obtaining further details about the case can contact The Gross Law Firm:

Address: 15 West 38th Street, 12th floor, New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

In conclusion, Regeneron shareholders who bought shares during the class period should utilize this opportunity to safeguard their interests and potentially recover losses through collective legal action. The Gross Law Firm’s commitment to ethical practices in the business world emphasizes the importance of transparency and accountability, particularly in the pharmaceutical industry where patient and investor interests must be prioritized.

This class action represents a critical juncture for shareholders impacted by the company's alleged misconduct. Taking prompt action is paramount to securing their rights and contributing to a significant legal process designed to ensure corporate responsibility.